HGSI (HUMAN GENOME SCI)
All Pro Portfolios with HGSI
- Total Pro Portfolios with HGSI:
- Kinetics Medical MEDRX
- show more
All Do-It-Yourself Portfolios with HGSI
- Total Do-It-Yourself Portfolios with HGSI:
- Lloyd's Portfolio 1
- Hepatitis C Stocks
- SamBeskur Portfolio 1
- james turano
- Speculative basket
- Horse Race Portfolio 1
- maxum23ft
- SandeepShah Portfolio 1
- Rich's Retirement
- marlastruyk Portfolio 1
- SUPRATRADE THURSDAY PICK V
- spinoza Portfolio 1
- SUPRATRADE PANTERA III
- stang3308 Portfolio 1
- brian picks
- April 07 madness
- BioquestII
- see what happen
- scjs4r speculative
- Barron's Insider Purchases 7-9-07
- scharpma Portfolio 1
- mauitan01 Portfolio 1
- tru spec
- BW's Equities
- Jerry1949 Portfolio 1
- john99 Portfolio 1
- cobbman Portfolio 1
- hesie74 Portfolio 1
- A mixed bag
- show more
- 58
- keith Portfolio 2
- Eric Sizemore Portfolio 1
- Dadz Watch
- Rick Clanton Portfolio 1
- teymour Portfolio 1
- DCastor Stocks
- RJ Main
- vedemre Portfolio 1
- SUPRATRADE XELLERON 8
- Kudzai's
- sgraber Portfolio 1
- R/D bio/pharm
- zimmys best
- arnief51 Portfolio 1
- SHOW ME THE $$$$$
- salesguy Portfolio 1
- rchamberlain Portfolio 1
- abd Portfolio 1
- MR
- biobombs
- bobarb45 Portfolio 1
- mattw2411
- BuildingWealth
- prricher Portfolio 1
- jim taich Portfolio 1
- Don Pompliano Portfolio 1
- jpd3175
- PART 5 JPMorgan 26th Annual Healthcare Conf 1/9/08..3rd Day Reporting Companies..Nymph Take
- Kathy's picks
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:katie7ch |
Date:07 01 08 |
Pluto in Capricorn play. DNA is the infrastructure of the cell. I expect a revolution/evolution from the information gathered from this research. Lots of $$$ to be made here. |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Human Genome Sciences (HGSI) was downgraded from Buy to Hold, Citigroup said. $8 price target. Swap of Syncria royalties for full rights to train adds further risk to the model. Also dashes M&A hopes. |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Human Genome Sciences (HGSI) was upgraded to Outperform, Bear Stearns said. While Albuferon risk has increased, the product could still reach the market. Company still has a solid cash position. $10 price target. |
|
Not yet rated
Rate now:
|
|
By:jpd3175 |
Date:11 27 07 |
growth no dividend but large potential in the bio field |
|
Not yet rated
Rate now:
|
|
Date:10 10 07 |
|
Great pipeline |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Upgraded by Lazard Capital from Sell to Hold |
|
Not yet rated
Rate now:
|
|
By:Barrons |
Date:07 07 07 |
The CFO recently purchased 10,000 shares or $91,000 worth of stock. |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Downgraded by Lehman Brothers from Overweight to Equal-weight |
|
Not yet rated
Rate now:
|
|
By:bobhart98 |
Date:05 23 07 |
It doesn't yet have a marketed product, but Albuferon is in phase III and shows promise. The company has enough money to bring Albuferon up and has more promising phase II & III drugs in development with GSK. |
|
Not yet rated
Rate now:
|
|
By:Bioquestor |
Date:05 02 07 |
very speculative- Phase II and III drugs look promising |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
By:sefredri |
Date:09 27 07 |
Expected to be a leading in using human genomics for specialized pharma |
|
Not yet rated
Rate now:
|
|
By:luvdasnail |
Date:06 18 07 |
picked up on speculative drug releases. has only depriciated |
|
Not yet rated
Rate now:
|
|